- SID Score
- 7.9/10
- Fair value
- $309.73
- Generated
- Nov 16, 2026
- Model
- claude-haiku-4-5-20251001
Johnson & Johnson is trading at $284.93 with a market capitalization of $505.8 billion, representing a mature healthcare leader with mixed valuation signals. The company exhibits a SID Score of 7.9/10, indicating solid overall quality, though the P/E ratio of 20.3x suggests the stock is trading at a premium to historical averages. With a fair value estimate of $309.73, the stock presents an 8.4% upside potential, though this conflicts with the analyst consensus price target of $207.08, signaling significant analytical disagreement in the market.
Recent earnings performance has been consistently strong, with JNJ beating earnings expectations across all four quarters examined, including Q4 2026 EPS of $2.59 versus the estimate of $2.53. The company demonstrates a Grade A in Growth and Momentum factors, indicating robust operational expansion and market performance, though a Grade C in Profitability raises questions about margin sustainability despite top-line growth. The dividend yield of 0.02% is notably low, suggesting limited income generation from dividends despite a Grade B in the Dividends factor, and the Value grade of D indicates the stock may be overvalued on traditional metrics at current price levels.
The stock is trading above both its 50-day moving average of $266.86 and 200-day moving average of $250.17, with the price positioned 6.8% above the 50-day MA and 13.9% above the 200-day MA, indicating a strong uptrend. However, the RSI(14) reading of 69.9 suggests the stock is approaching overbought territory, typically indicating potential for a pullback or consolidation in the near term. The technical setup presents a mixed signal where momentum remains positive but valuations may face headwinds from mean reversion.
Analyst & Insider Sentiment
The analyst consensus is "Buy" with an average price target of $207.08, which is notably 27.3% below the current trading price, creating a stark disconnect between the consensus rating and price objective. Insider activity shows mixed signals with both a buy and sell of 13,072 shares by Forminard Elizabeth on the same date (November 12, 2026), while other insiders including Woods, Pinto, and Hewson made modest purchases totaling 430 shares in September, suggesting limited conviction in either direction. The neutral news sentiment further supports the lack of strong directional bias from market participants.
The primary risk is valuation compression, as the stock's current price of $284.93 significantly exceeds the analyst average target of $207.08, creating substantial downside exposure if consensus views prove accurate. The low dividend yield of 0.02% leaves minimal downside cushion typical of dividend aristocrat stocks, while the overbought RSI reading of 69.9 indicates technical vulnerability to profit-taking or market corrections. Additionally, the conflicting signals between the fair value estimate ($309.73) and analyst consensus target ($207.08) suggest high uncertainty about intrinsic value and increased risk of unexpected repricing.
Johnson & Johnson presents a paradoxical investment opportunity where strong operational performance and analyst "Buy" ratings contrast sharply with valuation concerns and technical overbought conditions. For value-conscious investors, the current price appears stretched given the D-grade valuation score and analyst target implying 27% downside, suggesting waiting for a pullback to the $250-$266 range near moving average support. Growth-oriented investors may appreciate the Grade A momentum and consistent earnings beats, but should recognize the significant analyst price target disconnect and may consider this a sell rather than accumulate signal, particularly given the technical overbought condition and limited margin of safety at current levels.